The short answer: how much weight can you lose on Ozempic?
Ozempic (semaglutide) is FDA-approved to improve blood sugar in adults with type 2 diabetes, not for weight loss. Weight loss is a well-documented secondary effect, which is why people ask about it and why some clinicians prescribe it off-label. On Ozempic's highest dose (2 mg once weekly), the drug's labeling and clinical data show an average loss of roughly 14 lb, about 6.4 kg, over 40 weeks in people with type 2 diabetes (Ozempic Prescribing Information; Drugs.com, 2026).
That is meaningfully less than what the medications specifically approved for weight management deliver, for two reasons. First, Ozempic tops out at 2 mg, while its weight-loss sibling Wegovy uses a higher 2.4 mg dose. Second, most Ozempic weight data comes from people with type 2 diabetes, who tend to lose somewhat less weight than people without diabetes on the same drug.
If your goal is weight loss specifically, the more relevant numbers come from Wegovy, Zepbound, and Mounjaro's pivotal trials, covered below. A licensed clinician is the person who decides which medication, if any, fits your health history — this page is educational and not medical advice.
How much weight loss by drug: the trial numbers
Here is what the large, registrational (FDA-submitted) trials actually reported. Every figure below is a mean (average) total-body weight change versus baseline, alongside a placebo group that also received lifestyle counseling.
Wegovy (semaglutide 2.4 mg): In STEP-1, 1,961 adults with overweight or obesity (without diabetes) lost an average of 14.9% of body weight at 68 weeks, versus 2.4% on placebo. About one-third of participants lost 20% or more (NEJM, 2021).
Zepbound (tirzepatide): In SURMOUNT-1, 2,539 adults with obesity (without diabetes) lost an average of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, versus 3.1% on placebo. At 15 mg, 57% of participants lost at least 20% and 91% lost at least 5% (NEJM, 2022).
Mounjaro (tirzepatide): Same active ingredient and same doses as Zepbound, but FDA-approved for type 2 diabetes rather than weight loss. When prescribed off-label for weight, the SURMOUNT-1 numbers are the best guide to the molecule's ceiling, though people with diabetes often lose somewhat less.
Ozempic (semaglutide, 2 mg): Not approved for weight loss; roughly 14 lb / 6.4 kg over 40 weeks at the top diabetes dose.
By-dose and by-time: the expectation curve
Weight loss on GLP-1 medications is gradual and dose-dependent — it builds over many months, not weeks, and higher maintenance doses generally produce more loss. This is why comparing a friend's result at month 2 to yours at month 8 is misleading.
Dose matters. The clearest illustration is SURMOUNT-1's monotonic dose response for tirzepatide: 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. More drug, more average loss — though the jump from 10 to 15 mg was smaller than from 5 to 10 mg, suggesting the curve begins to flatten near the top (NEJM, 2022). Both Wegovy and Zepbound are titrated slowly over roughly 16-20 weeks to reach the target dose, partly to limit gastrointestinal side effects.
Time matters. The headline averages were measured at 68 weeks (Wegovy) and 72 weeks (Zepbound) — about 16 to 17 months. Weight typically comes off fastest in the first several months and then decelerates as you approach the plateau. Someone three months in has usually reached only a fraction of the full-trial average, which is normal, not failure.
Because titration is gradual, the first weeks (at the lowest starter doses) often bring little scale movement; the appetite and weight effects strengthen as the dose steps up. Only a clinician should set or change your dose or schedule.
What changes YOUR result (not the average)
Trial averages hide a wide spread. In STEP-1, some people lost far more than 15% and some far less. The factors below are the biggest reasons two people on the same drug end up in very different places.
None of these are things to self-adjust — dose, medication choice, and how to combine treatment with diet and activity are clinician decisions. They are listed here so you understand the sources of variation.
- Dose reached: People who titrate up to and tolerate the higher maintenance dose lose more on average than those who stay low or stop early — the whole reason Zepbound's 15 mg arm beat its 5 mg arm.
- Adherence and persistence: Missed doses, early discontinuation, and gaps in supply all pull results below trial averages, where dosing was tightly controlled. Real-world semaglutide studies consistently show smaller losses than the trials, partly due to lower adherence.
- Diet and physical activity: Every pivotal trial paired the drug with reduced-calorie eating and increased activity. The medication reduces appetite; the lifestyle changes still do real work. Adequate protein and resistance exercise also help preserve muscle as you lose weight.
- Starting weight and body composition: Results are usually reported as a percentage of body weight, so a higher starting weight can translate to more total pounds lost for the same percentage. Individual metabolism and biology vary.
- Diabetes status: People with type 2 diabetes tend to lose somewhat less weight than people without diabetes on the same GLP-1 dose — one reason Ozempic and Mounjaro (diabetes drugs) often show smaller weight numbers than Wegovy and Zepbound.
- Other medications and health conditions: Some medications and conditions affect weight independently; this is exactly what a prescribing clinician reviews before and during treatment.
A realistic monthly pace (and why to ignore weekly weigh-ins)
Averaged across the full trials, roughly 15% loss over ~68 weeks works out to somewhere around 1% of body weight per month — but that average is deceptive because the pace is front-loaded and dose-dependent. Early months on higher maintenance doses tend to move faster; later months slow as you near the plateau.
A common, clinically discussed benchmark for weight-management medications is losing at least 5% of body weight within the first few months of reaching a therapeutic dose, which many people on GLP-1s exceed. If weight is not moving as expected, that is a conversation for your clinician, not a cue to change your own dose.
Day-to-day scale readings swing with water, sodium, and digestion. A monthly trend line is far more informative than any single morning's number. For an overview of typical trajectories across the class, see our companion page on GLP-1 weight-loss results.
The plateau: why weight loss slows and stops
Almost everyone reaches a plateau, and it is expected, not a malfunction. In the pivotal trials, average weight loss curves flattened as participants approached 60-72 weeks — the body reaches a new equilibrium where intake, the medication's appetite effect, and energy expenditure balance out.
Several things drive the plateau: you are now at your maintenance dose (no further dose-driven push), a smaller body burns fewer calories at rest, and appetite-regulating hormones adapt. This is normal physiology, seen with essentially every weight-loss method.
Importantly, trial data show that weight loss is generally maintained while treatment continues, and studies of stopping the medication (such as the STEP-1 extension) show that much of the lost weight tends to return over the following year once the drug is discontinued. Whether GLP-1 therapy is short-term or long-term is a medical decision made with your clinician, based on your health goals and how you respond.
Head-to-head: does one drug beat another?
Yes, in the one large trial that compared them directly. SURMOUNT-5 (NEJM, 2025) randomized adults with obesity but without diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Average weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide — tirzepatide was superior on weight and waist circumference.
That does not make tirzepatide the right choice for everyone. Side-effect tolerance, other health conditions, insurance and cost, injection preferences, and drug availability all factor in — and both drug classes share gastrointestinal side effects, mostly mild to moderate and concentrated during dose escalation. A clinician weighs these trade-offs against your specific situation.
If you're comparing options, our per-drug pages break down each medication in detail, and our provider comparison can help you find licensed telehealth clinicians who prescribe GLP-1s — they, not this page, determine what's appropriate for you.
Trial averages are not a promise
Everything above comes from controlled clinical trials with structured dosing, lifestyle support, and monitored participants. Your real-world result can be higher or lower, and the honest framing is that these numbers describe what happened to a group, not what will happen to you.
We compare GLP-1 medications and licensed telehealth providers; we do not prescribe, sell, or manufacture these drugs. Note also that compounded semaglutide or tirzepatide — sometimes marketed as cheaper alternatives — are not FDA-approved finished drugs and are not the products these trials studied; their weight-loss results have not been established in trials of the same rigor.
The single most useful next step is a conversation with a licensed clinician who can review your health history, set expectations for your situation, and decide whether a GLP-1 medication fits. This page is educational only and is not medical advice.